Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$12.48
-1.3%
$10.09
$4.11
$28.68
$83.28M2.97172,665 shs22,768 shs
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$1.06
+6.8%
$0.98
$0.65
$1.75
$59.19M-0.02517,340 shs432,379 shs
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
$0.29
$0.15
$0.84
$10.93M1.3160,047 shs1.27 million shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$0.86
+3.8%
$0.58
$0.38
$8.98
$76.77M1.76619,015 shs522,931 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-1.34%+0.32%+10.25%+118.95%+58,767.92%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
+6.84%+12.78%+1.92%+39.47%+105,999,900.00%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.00%0.00%0.00%0.00%0.00%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
+3.84%+43.41%+40.93%+86.20%-88.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.5453 of 5 stars
3.54.00.00.00.61.70.6
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1.4919 of 5 stars
3.50.00.00.01.20.00.6
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
3.6169 of 5 stars
3.11.00.04.70.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$61.00388.78% Upside
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
3.00
Buy$7.33591.82% Upside
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
3.00
Buy$2.50∞ Upside
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.20
Hold$8.00828.18% Upside

Current Analyst Ratings Breakdown

Latest MDNA, FBRX, IRD, and VRCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
5/14/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/11/2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
4/9/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$10.99M5.75N/AN/A$0.21 per share5.05
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$7.57M10.53N/AN/A($0.11) per share-7.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$57.53M-$2.10N/AN/AN/A-429.42%-283.28%-144.32%8/12/2025 (Estimated)
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$76.58M-$1.20N/AN/AN/AN/AN/A-145.63%8/13/2025 (Estimated)

Latest MDNA, FBRX, IRD, and VRCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.89-$1.37-$0.48-$1.37N/AN/A
5/15/2025Q1 2025
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 million
5/13/2025Q1 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.14-$0.10+$0.04-$0.10$2.53 million$3.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
5.22
5.22
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
N/A
1.98
1.98
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/A
9.57
9.57
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/A
1.34
1.26

Institutional Ownership

CompanyInstitutional Ownership
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
14.97%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
12.38%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Insider Ownership

CompanyInsider Ownership
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
6.60%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
33.10%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
54.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
56.58 million6.20 millionOptionable
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
1459.66 million55.72 millionN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
1669.64 million46.59 millionNot Optionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4092.49 million42.55 millionOptionable

Recent News About These Companies

Verrica Shareholder Sues Board Over FDA Approval Hurdle Claims

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$12.48 -0.17 (-1.34%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$12.60 +0.12 (+0.96%)
As of 07/8/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Opus Genetics stock logo

Opus Genetics NASDAQ:IRD

$1.06 +0.07 (+6.84%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.04 -0.02 (-1.42%)
As of 05:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Medicenna Therapeutics stock logo

Medicenna Therapeutics NASDAQ:MDNA

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Verrica Pharmaceuticals stock logo

Verrica Pharmaceuticals NASDAQ:VRCA

$0.86 +0.03 (+3.84%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$0.84 -0.03 (-3.00%)
As of 06:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.